Summary.-Two 3-methylcholanthrene and a spontaneous BALB/c fibrosarcoma were examined for tumour-associated antigens (TAA) by in vivo and in vitro induction of tumour-immune responses. When BALB/c mice were immunized to these fibrosarcomas by surgical tumour removal, cross-reacting tumour-associated transplantation antigens (TATA) were detected on all 3 tumours. Cytotoxic effector cells (CL) were then induced in vitro by co-culture of BALB/c spleen cells with the spontaneous, or one of the carcinogen-induced fibrosarcomas. These CL were shown to be cytotoxic T cells (Tc) and to be directed against cross-reacting TAA on all 3 tumours, by two in vitro 51Cr-release assay systems, direct 51Cr-release cytotoxicity and cellular competitive inhibition of 51Cr release. Further studies demonstrated that the fibrosarcoma TAA involved in in vitro induction of Tc were not present on normal adult or foetal tissues. A secondary cytotoxic response was also detected in vitro when spleen cells from mice immunized to a carcinogen-induced fibrosarcoma were tested. The patterns of cross-reactivity detected by the in vivo and primary in vitro tumour-immune responses suggested that the TAA detected in vivo (TATA) were not identical to the TAA detected in vitro.
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THE first conclusive demonstration that tumours expressed specific tumour-associated antigens (TAA) was performed by Gross in 1943, using a 3 methylcholanthrene induced C3H murine sarcoma. Subsequent experimentation in highly inbred laboratory animals has firmly established the concept of TAA and, in particular, of "unique" tumour-associated transplantation antigens (TATA) on chemically induced tumours (Foley, 1953; Prehn and Main, 1957; Klein et al., 1960; Old et al., 1962) . In vivo studies with chemically induced tumours in the ensuing years have generally confirmed these observations (Baldwin, 1973; Wahl et al., 1974; Forbes, Nakao and Smith, 1975; Fritze et al., 1976) . However, in a few studies, shared TATA on chemically induced tumours have also been demonstrated (Koldovsky and Svoboda, 1963; Reiner and Southam, 1967; Robert, 0th and Dumont, 1973) .
The introduction of in vitro methods for the study of TAA has, however, revealed a widespread sharing of TAA among chemically induced tumours. Crossreacting TAA have been detected in vitro both by serological techniques (Harder and McKhann, 1968; Hellstrom, Hellstrom and Pierce, 1968; Tachibana and Klein, 1970; Burdick and Wells, 1973; Fritze et at., 1976) and by assays of cellmediated immunity where lymphoid cells from tumour-bearing or tumour-immune hosts were tested against various tumour cell lines (Hellstrom et al., 1968; Takasugi and Klein, 1970; Bataillon, Ross and Klein, 1975; Forbes et al., 1975; Whitney, Levy and Smith, 1975) .
The in vivo specificity of immunity to chemically induced tumours has been ascribed to the immunization of T lymphocytes by "unique" TATA  Kearney, Basten and Nelson, 1975; Whitney et al., 1975) . The in vitro cross-reactivity ofimmunity, on the other hand, has been shown to vary both with the source of the effector cell (Bataillon et al., 1975) and with the timing of cell harvest after immunization (Kearney et al., 1975) . The introduction of wholly in vitro methods for the induction and assay of tumour-specific immunity has provided another means of examining the TAA antigens of chemically induced tumours. McKhann and Jagarlamoody reported in 1971 the successful in vitro immunization of C3H spleen cells against 2 C3H 3-methylcholanthrene-induced fibrosarcomas. The immune lymphocytes (CL) were assayed both in vitro, on 3H-thymidine-labelled fibrosarcoma cells, and also in vivo in Winn-type assays (Klein et al., 1960; Winn, 1961) where CL admixed with tumour cells were inoculated into syngeneic mice. The in vivo Winn assay results showed clear-cut specificity of in vitro immunization to "unique" TAA on each of the tumours, but the in vitro 3H-thymidine-release assay with the same CL demonstrated some cross-reactivity between the 2 fibrosarcomas. Subsequent studies have confirmed the in vitro immunization of lymphocytes by TAA on carcinogen-induced tumours (Warnatz and Scheiffarth, 1974; Small and Trainin, 1975; Kall and Hellstrom, 1975) . However, conflicting results have emerged from these in vitro experiments, with claims both that the specificity of the in vitro tumour specific immunity induced is to unique TAA alone (McKhann and Jagarlamoody, 1971; Kall, Hellstrom and Hellstrom, 1976 ) and that it is to both crossreacting and unique TAA on the same tumour cells (Warnatz and Scheiffarth, 1974) . The identity of the effector cytotoxic cells in these in vitro systems was not described. This paper presents our experience with both in vitro and in vivo induction of tumour-specific immunity to 3 BALB/c fibrosarcomas, with particular reference to the TAA involved. Also included is data which indicates that the in vitro cytotoxic cell is a T lymphocyte.
MATERIALS AND METHODS
Media.-Eagle's minimal essential medium with non-essential amino acids (Grand Island Biological Co., NY) was used supplemented with 10% foetal calf serum (FCS) (Commonwealth Serum Laboratories) 100 u/ml of penicillin, 100 iig/ml of streptomycin and buffered with sodium bicarbonate (MEMF). The medium was prepared fresh each day, and 2-mercaptoethanol (2ME) was added to a final concentration of 10-4M. The assay was performed in Dulbecco's modified Eagle's medium (Commonwealth Serum Laboratories, Melbourne, Australia) supplemented with 10% FCS (DMEF).
Animals.-Inbred male mice, aged 6-10 weeks, from the Hall Institute BALB/c An/ Bradley/WEHI specific-pathogen-free colony, were used throughout this study.
Tumours.-Three BALB/c fibrosarcomas were used in this study, and were adapted to tissue culture early in their transplantation history. WEHI-164 and WEHI-167 are 3-methylcholanthrene-induced BALB/c fibrosarcomas whose origins and adaptation to tissue culture have been described previously . WEHI-1l is a BALB/c fibrosarcoma which arose spontaneously, and was adapted to tissue culture by a technique described previously . The tissue-culture lines of WEHI-164 and WEHI-1l were used for all the in vitro experiments involving these 2 tumours, whereas in the in vivo experiments the immunizations were performed with in vivo-derived cells, and the tumour challenge with either in vivo-or in vitro-derived cells.
WEHI-167, however, proved difficult to maintain in tissue culture, and was therefore inoculated into BALB/c mice and maintained in serial passage in vivo. The WEHI-167 tumour cells used in this study were derived from cell suspensions prepared from in vivo tumours according to the method of von Boehmer and Shortman (1973) . This technique removes dead cells and cellular debris from the suspension, leaving a single-cell tumour suspension of over 80% viability as determined by eosin dye exclusion. EL-4, a C57BL T lymphoma maintained in tissue culture, was used for the demonstration of specificity in the inhibition assay, and was kindly provided by Dr Alan Harris.
In vivo immunization.
-The 3 fibrosarcomas were tested for the presence of TATA in BALB/c mice by the technique of surgical tumour removal as previously described (Rollinghoff, Rouse and Warner, 1973; . Briefly, the minimum tumour dose (MTD) of viable tumour cells capable of initiating lethal tumour growth in 100% of inoculated BALB/c mice was determined for each tumour. Groups of BALB/c mice were then injected in the right hind leg with a dose in excess of this, and the legs amputated under ether anaesthesia when the tumour became palpable. Two weeks later these mice were challenged, together with age-and sex-matched BALB/c controls, s.c. on the right flank with the MTD of the immunizing tumour. The mice were then observed 2-3 times weekly and the tumour diameters determined by taking the mean of 2 transverse measurements of the tumour mass.
In the cross-immunity experiments, twice as many BALB/c mice were immunized by this procedure, and half challenged with the MTD of the immunizing tumour, and half with the MTD of the tumour being tested for cross immunity.
In vitro induction and assay of tumourspecific immnunity.-The techniques have been previously described in detail, and so are only outlined here.
Induction procedure (Burton, Thompson and Warner, 1975) .-Square 100mm tissueculture trays partitioned into 25 compartments (Sterilin Ltd, Richmond, Surrey, England) were used. Varying numbers of irradiated (5000 rad) stimulator fibrosarcoma cells, in a volume of 0-1 ml, were placed into the compartments and 3-6 ml of MEMF added. Then 15 x 106 viable nucleated responder BALB/c spleen cells (in 0-2 ml) were added to each compartment, and the trays placed in a humidified incubator at 37°C in 10% CO2 in air for 5 days; these conditions being optimal for the induction of tumour-specific immunity. This method was adopted in order to produce responder/ stimulator curves for the various in vitro direct cytotoxicity experiments. Groups of 10 identical compartments were set up for each ratio, and stimulator cell numbers, in the range of 1-5 X 102-1-5 x 105 per compartment, were used. In addition, irradiated (5000 rad) C57BL stimulator spleen cells were used to alloimmunize BALB/c responder lymphocytes in vitro by culturing the 2 cell types together as described above, but at a responder/stimulator (R/S) ratio of 10/1. BALB/c responder spleen cells alone or with 1-5 x 106 irradiated (5000 rad) syngeneic stimulator BALB/c spleen cells.
At Direct 51Cr-release cytotoxic assay (Burton et al., 1975 and 6-25 x 106 CL in 100 ,u of DMEF were dispensed into wells and then 25 x 103 labelled tumour target cells in 100 ,ul of DMEF were added.
The standard assay time was 4 h at 37°C followed by an additional hour at 45°C to facilitate the release of 5ICr from the lysed tumour target cells. Then 100 ,ul of supernatant was removed from each of the background and test assay wells, while from the Zaponin dilution wells 100lO aliquots from 2 wells were pooled, since each well contained half the number of targets. These samples were counted on a Beckman Biogamma scintillation counter, and the percent specific lysis computed as Percentage specific lysis= test count-background count X 100 maximal count -background count Inhibition assay . Anti-Thy-1.2 treatment.-Anti-Thy-1.2 sera was prepared and supplied by Ms J. Gamble. Its mode of production, cytotoxic titre and specificity for T cells have been described in detail . In vitro-induced CL were treated with the serum at a dilution of 1:3 for 30 min at 37°C, after which they were resuspended in a 1:6 dilution of agarose-absorbed guinea-pig complement for a further 30 Table I .
The cross-immunity experiments, however, produced some unexpected findings. In the first instance, there was strong cross immunity between WEHI-11 and WEHI-164, indicating a highly immunogenic shared TATA. Although readily detectable in reciprocal immunization and (Klein et al., 1960 Ilfeld, Carnaud, and Klein, 1975) . We have extensively investigated this phenomenon and so only include here illustrative data relevant to the fibrosarcomas (Table II) and it has been shown that the kinetics of seen that BALB/c spleen cells 51Cr release after target cell lysis by CL significant cytotoxicity for 51Cr-do vary with the cell line (Sanderson, I WEHI-164 when they are cul-1976). lone, or with irradiated BALB/c On the basis of these experiments, R/S cells at a R/S ratio of 10/1. There is ratios of 10,000/1 for WEHI-li were ificant difference in the cytotoxicity chosen as optimal for the induction of CL. ctetectect between these two induction modes. However the in vitro induction of tumour-immune CL from the same spleen cell pools against WEHI-164 at the optimal R/S ratio (1000/1) resulted in CL that were significantly more cytotoxic Cross immunity between fibrosarcomas in vitro: inhibition studies W"hen BALB/c CL were induced in vitro to and assayed on the same 51Cr-labelled fibrosarcoma, WEHI- 164 and WEHI-i both inhibited lysis of the labelled target cell to the same extent ( Fig. 4(a) ). Normal adult BALB/c spleen cells did not inhibit lysis significantly, indicating that the antigens involved were not present on this normal tissue. In the corresponding experiment in which unlabelled WEHI-164 and WEHI 11 were added to BALB/c CL induced in vitro to WEHI-1l, and 51Cr-labelled WEHI-11, there was a similar result. Both fibrosarcomas caused comparable high levels of inhibition over the blocker/target ratio range employed (Fig. 4(b) ). In this second experiment, in addition to the normal spleen-cell control, viable 14-day BALB/c foetal liver cells were also added over the blocker/target ratio range shown. However, as with the adult spleen cells, there were no significant inhibition of lysis. These results indicate that WEHI-164 and WEHI-lI share TAA as detected by these in vitro techniques, and hence confirm both the in vivo and direct in vitro cytotoxicity experiments. Furthermore they also indicate that the TAA detected are not oncofoetal or self antigens.
The final inhibition experiment was performed over a different range of blocker/target ratios, and also included WEHI-167, prepared from an in vivo tumour as described earlier. In this experiment all 3 fibrosarcomas, WEHI-164, WEHI-167 and WEHI-11, caused significant inhibition of the lysis of 51Cr-labelled WEHI-164 by BALB/c CL induced in vitro to that tumour (Fig. 5) . Furthermore, over this range of blocker! target ratios, differences in inhibition between the 3 tumours were apparent.
For, although all 3 caused 100% inhibition at a blocker/target ratio of 30/1, indicating that there was no significant qualitative difference in TAA expression, there were significant differences in inhibition at the 3/1 blocker/target ratio. . These include nonspecific inhibition, which is particularly troublesome with large tumour cells at high blocker/target ratios. For the pur poses of this paper, an inhibition assay which demonstrates that WEHI-164, the largest of the cell lines used, does not inhibit non-specifically at blocker/target ratios of 20/1 or less is included (Fig. 6 (Rollinghoff and Wagner, 1973; (Rollinghoff, 1974 ) and a recent report indicates a similar secondary response to murine sarcomas (Kall et al., 1976 (Prehn, 1975) . Tumours that appear rapidly after a high dose of carcinogen are more immunogenic than those that arise a long time after a small dose. Furthermore, it has also been shown that spontaneous malignant neoplasms of mice may, in general, be non-immunogenic (Hewitt, Blake and Walder, 1976 . These in vivo results exemplify the need carefully to titrate tumours in the strain of origin, so that too large a challenge dose is not used.
The results of the in vitro induction of cytotoxic lymphocytes to these fibrosarcomas has demonstrated a complete sharing of antigens between the 3 tumours. The response as revealed by anti-Thy-1.2 serum treatment, is completely mediated by cytotoxic T lymphocytes, as was found for the in vivo response to the fibrosarcoma WEHI-164 (Rollinghoff and XVarner, 1973) . Since all 3 tumours completely inhibited the cytotoxic activity directed against one of them, a common antigenic determinant is involved. The degree of Responder spleen cells* inhibition observed at blocker/target ratios of less than 30/1 is due to specific inhibition and not to the non-specific inhibition observed by these tumours at higher ratios (Fig. 6 ). The nature of this common antigenic determinant has not been fully defined, but is clearly shown to be distinct from the oncofoetal antigens also expressed by these tumours since foetal liver shows no significant blocking in this system, whereas it does so in the OFA studies . The possibility that sensitization to foetal calf serum components is involved has been discussed elsewhere in detail but is not the explanation for this common antigen, since the WEHI-167 cells were derived from in vivo tumour, not from a cultured line.
